



RaQualia Pharma Inc.  
ASKA Pharmaceutical Co., Ltd.  
June 9, 2023

**Termination of the Joint Research Agreement  
Regarding the Drug Discovery Targeting Specific Ion Channels**

June 9, 2023, Nagoya and Tokyo - RaQualia Pharma Inc. (Head Office: Nagoya, Aichi, Japan; President & CEO: Hirobumi Takeuchi; "RaQualia Pharma") and ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; President and Representative Director: Sohta Yamaguchi; "ASKA") announced today that they have decided to terminate the joint research agreement between the two companies ("Agreement") regarding the joint research on the drug discovery targeting specific ion channels ("Joint Research").

RaQualia Pharma and ASKA have conducted the Joint Research since July 2019, aiming to discover new drugs. As a result of the discussion regarding the conduct of further joint research using the results of the Joint Research ("Joint Research Results"), the two companies have decided to terminate the Joint Research Agreement by mutual consent. Upon termination of the Joint Research Agreement, the Joint Research Results will belong to RaQualia Pharma, and RaQualia Pharma will continue the research and development to deliver new drugs independently.

About Ion Channels:

Ion channels are membrane proteins that allow ions to pass across cell membranes. Ion channels are involved in various physiological functions, such as nerve signaling, muscle contraction, and hormone secretion. Ion channel modulators have the potential to treat a wide range of diseases.

RaQualia Pharma Inc.  
Business Management  
Phone: +81-(0)52-446-6100  
E-mail: [ask@raqualia.com](mailto:ask@raqualia.com)

ASKA Pharmaceutical Co., Ltd.  
Corporate Planning Department  
Phone: +81-(0)3-5484-8366  
E-mail: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)